Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Ponatinib
72
CHF
CHF 72.00
In stock
SYN-1116-M0011 mgCHF 72.00
SYN-1116-M0055 mgCHF 108.00
SYN-1116-M01010 mgCHF 132.00
SYN-1116-M05050 mgCHF 437.00
SYN-1116-M100100 mgCHF 724.00
| Product Details | |
|---|---|
| Synonyms | AP24534 |
| Product Type | Chemical |
| Properties | |
| Formula | C29H27F3N6O |
| MW | 532.6 |
| CAS | 943319-70-8 |
| Purity Chemicals | ≥95% |
| Appearance | Solid. |
| Solubility | Soluble in DMSO or ethanol. |
| Declaration | Manufactured by SynKinase. |
| Other Product Data |
Target: Abl - BCR - FGFR | Kinase Group: PTK | Substrate: Tyrosine Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet. |
| InChi Key | PHXJVRSECIGDHY-UHFFFAOYSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Ponatinib is a potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC(50) values of 0.37, 1.1, 1.5, 2.2 and 5.4nM respectively.
Product References
- AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance: T. O'Hare, et al.; Cancer Cell 16, 401 (2009)
- Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant: W.S. Huang, et al.; J. Med. Chem. 53, 4701 (2010)
- Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies: J.M. Gozgit, et al.; Mol. Cancer Ther. 10, 1028 (2011)
Related Products
